DOI:
10.1055/s-00000068
Seminars in Interventional Radiology
LinksClose Window
References
Hack SP, Spahn J, Chen M. et al.
IMbrave 050: a Phase III trial of atezolizumab plus bevacizumab in high-risk hepatocellular carcinoma after curative resection or ablation.
Future Oncol 2020;
16 (15) 975-989
We do not assume any responsibility for the contents of the web pages of other providers.